Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On May 9, we upgraded Quest Diagnostics (DGX - Analyst Report), a leading player in the diagnostic testing market, to Neutral. In spite of disappointing first-quarter 2013 results, we are optimistic about the company’s recently adopted restructuring initiative as well as its focus on high potential areas such as core diagnostic information services.

Why the Upgrade?

Quest Diagnostics reported dismal results for the first quarter of 2013, missing the Zacks Consensus Estimate on both lines. Adjusted earnings per share (EPS) were 89 cents, down 15.3% year over year.Sales declined 6.4%, with a 6.7% drop in diagnostic information services revenues. The current market environment remained challenging in the form of commercial pricing pressures and Medicare cuts. We are also concerned with the overall soft industry trends leading to volume pressure. This was reflected in the conservative 2013 outlook.

However, the weak performance in the quarter has not deterred Quest Diagnostics’ focus on areas with high potential such as gene-based esoteric testing for cancer, cardiovascular disease, infectious disease and neurological disorders. As a part of this strategy, earlier in Apr 13, Quest completed the divesture of HemoCue diagnostics products business. Moreover, last December, the company shed its OralDNA Labs salivary-diagnostics business in order to refocus its resources toward core diagnostic information services. We also hold a favorable view regarding Quest Diagnostics’ recently implemented major organizational restructuring in order to increase operational efficiency and restore growth. We assume all these endeavors could very well turn around the company’s fortunes going ahead. The company now carries a Zacks Rank #3 (Hold).

Med-Tech Stocks That Warrant a Look

While we prefer to avoid Quest Diagnostics until we see signs of improvement in the company's performance, other medical device stocks worth a look are Conceptus, Inc. , VCA Antech Inc. (WOOF - Snapshot Report) and HEALTHSOUTH Corp. (HLS - Snapshot Report). All are Zacks Rank #1 (Strong Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%